Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Expert consensus on vitamin D in osteoporosis.

Annals of joint·2025

Same author

Quantum biology in low level light therapy: death of a dogma.

Annals of translational medicine·2020

Same author

Mitochondrial solar sensitivity: evolutionary and biomedical implications.

Annals of translational medicine·2020

Same author

Alternative Reaction Channels and Carbene Intermediates in the Ce<sup>4+</sup>-Malonic Acid and Ce<sup>4+</sup>-Bromomalonic Acid Reactions. 1. CO<sub>2</sub> Measurements.

The journal of physical chemistry. A·2020

Same author

Revisiting the Photon/Cell Interaction Mechanism in Low-Level Light Therapy.

Photobiomodulation, photomedicine, and laser surgery·2019

Same author

Mitochondrial cytochrome c oxidase is not the primary acceptor for near infrared light-it is mitochondrial bound water: the principles of low-level light therapy.

Annals of translational medicine·2019

Search research articles

Related Experiment Video

Updated: Dec 3, 2025

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Tutankhamun's Antimalarial Drug for Covid-19.

Andrei P Sommer¹, Horst-Dieter Försterling², Katlin E Sommer³

¹Faculty of Science, ISRA University, Amman.

|October 31, 2020

Summary

Drug repositioning identifies new uses for approved drugs, including antimalarials for COVID-19 treatment. Thymoquinone, from Nigella sativa, serves as a model for developing new antiviral therapies against SARS-CoV-2.

More Related Videos

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

Related Experiment Videos

Last Updated: Dec 3, 2025

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

Area of Science:

Pharmacology
Virology
Drug Discovery

Background:

Drug repositioning is crucial for identifying novel COVID-19 treatments.
Antimalarial drugs, targeting endosomal pH, were early candidates for SARS-CoV-2 therapy.
Thymoquinone, a natural compound from Nigella sativa, shows promise as an antiviral agent.

Discussion:

This study compares thymoquinone's antiviral mechanisms to conventional antimalarials.
A physicochemical model is developed to understand thymoquinone's interaction with SARS-CoV-2 and host cells.
The research explores thymoquinone's potential beyond its antimalarial properties.

Key Insights:

An irreducible parametric scheme is proposed for identifying potential COVID-19 drugs.
The study provides a generalizable framework for systematic drug selection and design.
Thymoquinone's historical context, including its presence in Tutankhamun's tomb, is examined.

Outlook:

The findings offer a novel approach to drug development for emerging viral infections.
The research may lead to more effective and targeted therapies for COVID-19.
Unexpectedly, the study suggests Tutankhamun may not have died from malaria.